...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....
...aptamer in cancer indications other than AML. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...or without 40 or 80 mg/kg/day AS1411. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...of AS1411 in AML in early 2010. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...was up 0.50p to 35.50p on Wednesday. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...it is also in Phase II testing. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...Society of Clinical Oncology meeting in Orlando. Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...16 evaluable patients (see BioCentury, July 14). Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...lung cancer (NSCLC) last week (see B17). Antisoma gained AS1411 in its 2005 acquisition of Aptamera Inc....

...II testing for acute myeloid leukemia (AML). Antisoma gained AS1411 through its 2005 acquisition of Aptamera Inc....

...AS1411 has Orphan Drug designation for pancreatic cancer. ASM gained AS1411 through its acquisition of Aptamera Inc....